Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 330 | 53 | 273 |
| Samples | 251 | 47 | 201 |
| Peptides | 195 | 33 | 160 |
Function
CTSC · Cathepsin C
This gene encodes a member of the peptidase C1 family and lysosomal cysteine proteinase that appears to be a central coordinator for activation of many serine proteinases in cells of the immune system. Alternative splicing results in multiple transcript variants, at least one of which encodes a preproprotein that is proteolytically processed to generate heavy and light chains that form a disulfide-linked dimer. A portion of the propeptide acts as an intramolecular chaperone for the folding and stabilization of the mature enzyme. This enzyme requires chloride ions for activity and can degrade glucagon. Defects in the encoded protein have been shown to be a cause of Papillon-Lefevre syndrome, an autosomal recessive disorder characterized by palmoplantar keratosis and periodontitis. [provided by RefSeq, Nov 2015].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 177 amino-acid changes on canonical ENST00000227266 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in CTSC · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in CTSC – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 2/40 5% | 0/0 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 6/133 5% |
| Acute Monocytic Leukemia | 0/1 0% | 1/25 4% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Endometrial Carcinoma | 1/42 2% | 11/612 2% |
| Colorectal Carcinoma | 14/143 10% | 35/3239 1% |
| Bladder Carcinoma | 1/58 2% | 11/956 1% |
| Melanoma | 3/210 1% | 20/1899 1% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Non-Small Cell Lung Carcinoma | 7/304 2% | 10/1390 1% |
| Gastric Carcinoma | 2/74 3% | 16/1809 1% |
| Other Solid Cancers | 2/94 2% | 11/1515 1% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
| Cervical Carcinoma | 0/35 0% | 3/422 1% |
| Ewings Sarcoma | 1/63 2% | 1/262 0% |
| Prostate Carcinoma | 0/13 0% | 13/2105 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 4/752 1% |
| Hepatocellular Carcinoma | 0/46 0% | 12/2210 1% |
| Germ Cell Tumour | 1/25 4% | 0/169 0% |
| Osteosarcoma | 1/45 2% | 0/166 0% |
| Burkitts Lymphoma | 0/32 0% | 1/196 1% |
| Other Sarcomas | 0/69 0% | 3/699 0% |
| Glioma | 0/52 0% | 7/2127 0% |
| Thyroid Gland Carcinoma | 2/45 4% | 3/1592 0% |
| Biliary Tract Carcinoma | 0/54 0% | 3/950 0% |
| Head and Neck Carcinoma | 0/85 0% | 5/1574 0% |
| Neuroendocrine Tumour | 2/154 1% | 0/577 0% |
| Esophageal Carcinoma | 0/23 0% | 2/769 0% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 2/810 0% |
| Non-Cancerous | 0/104 0% | 2/830 0% |
Mutation Distribution
Where CTSC is mutated · all tissues, split by cell line vs tissue
How many mutations in CTSC were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 330 mutations in CTSC
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|